|
PPAR gamma activation Clinical evidence
|
|
|
Evolution of clinical evidence supporting PPAR gamma activation
|
|
|
Anticipated results from large multicenter trials in (pre)diabetes
|
|
|
PROactive: Study Design
|
|
|
PROactive Baseline Characteristics
|
|
|
PROactive CV history at baseline
|
|
|
PROactive CV medications at baseline
|
|
|
Time to primary composite endpoint
|
|
|
Significant reduction in secondary outcome
|
|
|
Time to all-cause death, non-fatal MI, stroke or ACS
|
|
|
Time to permanent insulin use
|
|
|
PROactive Subgroup analysis – Previous MI
|
|
|
PROactive Subgroup analysis – Previous stroke
|
|
|
PROactiveHF hospitalization and mortality
|
|
|
TZDs associated with lower mortality
|
|
|
Summary
|
|
|
PROactive in perspective
|
|
|
PROactive vs landmark clinical trials
|
|
Share this page with your colleagues and friends: